8-KRegulation FDExhibits & Filings

AbbVie Inc. 8-K Report, Regulation FD Disclosure (Sep 16, 2019)

Filed September 16, 2019For Securities:ABBV

Summary

This 8-K filing by AbbVie Inc. (ABBV) on September 15, 2019, primarily serves to disclose information related to their pending acquisition of Allergan plc. It details AbbVie's obligations under Irish Takeover Rules, which require the repetition of their previously disclosed profit forecast for Q3 2019 and FY 2019 in a "Profit Forecast Document." This document also includes attestations from AbbVie's reporting accountants (PricewaterhouseCoopers UK) and financial advisor (Morgan Stanley) regarding the compilation and due care of the profit forecast. For investors, this filing underscores the ongoing progress of the Allergan acquisition and highlights the financial projections being shared with Allergan shareholders. AbbVie is also providing insights into its post-acquisition financial strategy, aiming for credit metrics to improve to 2.5x net debt to EBITDA by the end of 2021. This demonstrates a commitment to deleveraging and financial discipline following the significant transaction.

Key Highlights

  • 1AbbVie is proceeding with its acquisition of Allergan plc, with an acquisition subsidiary (Venice Subsidiary LLC) set to acquire all outstanding ordinary shares of Allergan.
  • 2The filing details AbbVie's compliance with Irish Takeover Rules by repeating its Q3 2019 and FY 2019 profit forecast.
  • 3Independent reports from PricewaterhouseCoopers UK and Morgan Stanley are included, attesting to the accuracy and due consideration of AbbVie's profit forecast.
  • 4AbbVie anticipates that the debt of the combined company will be largely pari passu post-acquisition.
  • 5New debt issued to finance the acquisition is expected to be dollar-denominated.
  • 6AbbVie targets an improvement in credit metrics to 2.5x net debt to EBITDA by the end of 2021, with further improvements expected thereafter.

Frequently Asked Questions

The main purpose of this 8-K filing is to provide updates and disclosures related to AbbVie's ongoing acquisition of Allergan plc, particularly concerning regulatory requirements in Ireland regarding profit forecasts and financial projections for the combined entity.

The Irish Takeover Rules are regulations governing takeovers in Ireland, which is where Allergan is incorporated. In this case, these rules require AbbVie to repeat its profit forecast and provide attestations from third parties due to the share component of the acquisition consideration.

AbbVie aims to improve its credit metrics, specifically targeting a net debt to EBITDA ratio of 2.5x by the end of 2021, with plans for further improvement in subsequent years. Any new debt used to finance the acquisition is expected to be dollar-denominated.

No, the reports from PricewaterhouseCoopers UK and Morgan Stanley are prepared specifically to comply with Irish Takeover Rules. The PricewaterhouseCoopers UK report is prepared in accordance with UK standards and does not constitute an audit or review under U.S. Generally Accepted Auditing Standards or PCAOB standards.